231 related articles for article (PubMed ID: 16914642)
21. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
22. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
[TBL] [Abstract][Full Text] [Related]
23. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.
Jun KY; Lee EY; Jung MJ; Lee OH; Lee ES; Park Choo HY; Na Y; Kwon Y
Eur J Med Chem; 2011 Jun; 46(6):1964-71. PubMed ID: 21419530
[TBL] [Abstract][Full Text] [Related]
25. Structural determinants of the catalytic inhibition of human topoisomerase IIα by salicylate analogs and salicylate-based drugs.
Bau JT; Kurz EU
Biochem Pharmacol; 2014 Jun; 89(4):464-76. PubMed ID: 24695359
[TBL] [Abstract][Full Text] [Related]
26. DNA damage, c-myc suppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells.
Lu HR; Meng LH; Huang M; Zhu H; Miao ZH; Ding J
Cancer Chemother Pharmacol; 2005 Mar; 55(3):286-94. PubMed ID: 15592835
[TBL] [Abstract][Full Text] [Related]
27. Hairpin structures formed by alpha satellite DNA of human centromeres are cleaved by human topoisomerase IIalpha.
Jonstrup AT; Thomsen T; Wang Y; Knudsen BR; Koch J; Andersen AH
Nucleic Acids Res; 2008 Nov; 36(19):6165-74. PubMed ID: 18824478
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
[TBL] [Abstract][Full Text] [Related]
29. Targeting the inverted CCAAT box 2 in the topoisomerase IIalpha promoter by JH-37, an imidazole-pyrrole polyamide hairpin: design, synthesis, molecular biology, and biophysical studies.
Henry JA; Le NM; Nguyen B; Howard CM; Bailey SL; Horick SM; Buchmueller KL; Kotecha M; Hochhauser D; Hartley JA; Wilson WD; Lee M
Biochemistry; 2004 Sep; 43(38):12249-57. PubMed ID: 15379563
[TBL] [Abstract][Full Text] [Related]
30. HMGB1 interacts with human topoisomerase IIalpha and stimulates its catalytic activity.
Stros M; Bacíková A; Polanská E; Stokrová J; Strauss F
Nucleic Acids Res; 2007; 35(15):5001-13. PubMed ID: 17636313
[TBL] [Abstract][Full Text] [Related]
31. Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha.
Hasinoff BB; Wu X; Krokhin OV; Ens W; Standing KG; Nitiss JL; Sivaram T; Giorgianni A; Yang S; Jiang Y; Yalowich JC
Mol Pharmacol; 2005 Mar; 67(3):937-47. PubMed ID: 15602006
[TBL] [Abstract][Full Text] [Related]
32. Functional compatibility between isoform alpha and beta of type II DNA topoisomerase.
Sakaguchi A; Kikuchi A
J Cell Sci; 2004 Mar; 117(Pt 7):1047-54. PubMed ID: 14996935
[TBL] [Abstract][Full Text] [Related]
33. In silico studies with human DNA topoisomerase-II alpha to unravel the mechanism of in vitro genotoxicity of benzene and its metabolites.
Pandey AK; Gurbani D; Bajpayee M; Parmar D; Ajmani S; Dhawan A
Mutat Res; 2009 Feb; 661(1-2):57-70. PubMed ID: 19059273
[TBL] [Abstract][Full Text] [Related]
34. DNA topoisomerase I and IIalpha expression in penile carcinomas: assessing potential tumour chemosensitivity.
Berney DM; Stankiewicz E; Adlan AM; Kudahetti S; Biedrzycki OJ; Hadway P; Watkin N; Corbishley C
BJU Int; 2008 Sep; 102(8):1040-4. PubMed ID: 18489530
[TBL] [Abstract][Full Text] [Related]
35. A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells.
Kao YH; Hsieh HP; Chitlimalla SK; Pan WY; Kuo CC; Tsai YC; Lin WH; Chuang SE; Chang JY
Anticancer Drugs; 2008 Feb; 19(2):151-8. PubMed ID: 18176111
[TBL] [Abstract][Full Text] [Related]
36. Salvicine inactivates beta 1 integrin and inhibits adhesion of MDA-MB-435 cells to fibronectin via reactive oxygen species signaling.
Zhou J; Chen Y; Lang JY; Lu JJ; Ding J
Mol Cancer Res; 2008 Feb; 6(2):194-204. PubMed ID: 18314480
[TBL] [Abstract][Full Text] [Related]
37. The N-terminal domain of human topoisomerase IIalpha is a DNA-dependent ATPase.
Gardiner LP; Roper DI; Hammonds TR; Maxwell A
Biochemistry; 1998 Dec; 37(48):16997-7004. PubMed ID: 9836594
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents.
Skladanowski A; Côme MG; Sabisz M; Escargueil AE; Larsen AK
Mol Pharmacol; 2005 Sep; 68(3):625-34. PubMed ID: 15942022
[TBL] [Abstract][Full Text] [Related]
39. Salvicine triggers DNA double-strand breaks and apoptosis by GSH-depletion-driven H2O2 generation and topoisomerase II inhibition.
Cai YJ; Lu JJ; Zhu H; Xie H; Huang M; Lin LP; Zhang XW; Ding J
Free Radic Biol Med; 2008 Sep; 45(5):627-35. PubMed ID: 18582559
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells.
Miao ZH; Tang T; Zhang YX; Zhang JS; Ding J
Int J Cancer; 2003 Aug; 106(1):108-15. PubMed ID: 12794765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
